Bellerophon Therapeutics is a
clinical-stage biotherapeutics company.
We are focused on developing innovative therapies in the treatment of cardiopulmonary diseases. Our mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need.
 Our lead investigational cardiopulmonary product candidate, INOpulse is a combination drug-device therapy that we are developing for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), and pulmonary hypertension associated with sarcoidosis (PH-Sarc). Our goal is to become a leader in developing and commercializing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. |
Bellerophon Therapeutics Inc. News Release A Collection of Bellerophon Therapeutics Inc. News Release Bellerophon Therapeutics Announces Completion of Enrollment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease
01/18/2023 09:05 PM
Enrollment concludes earlier than anticipated; pivotal top-line data now expected mid-2023 WARREN, N.J. , Jan. 18, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for Bellerophon Therapeutics Announces License Agreement for the Commercialization of INOpulse® in Greater China with Baylor BioSciences
01/05/2023 01:30 PM
Bellerophon to receive a license payment of $6 million, as well as royalties on net sales in Greater China WARREN, N.J. , Jan. 05, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing Bellerophon Provides Clinical Program Update and Reports Third Quarter 2022 Financial Results
11/14/2022 01:30 PM
Ongoing INOpulse® REBUILD Phase 3 trial enrollment completion expected in the first quarter of 2023, with pivotal top-line data readout anticipated in the third quarter of 2023 WARREN, N.J. , Nov. 14, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the Bellerophon Announces FDA Acceptance of Change to Ongoing Phase 3 REBUILD Study of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease
09/27/2022 12:30 PM
New study size of 140 patients for the REBUILD Study, without modifying trial objective or endpoints and maintaining power of >90% for the primary endpoint Independent Data Monitoring Committee agreed that the new targeted study size is appropriate Enrollment now expected to conclude in Q1 2023, Bellerophon Provides Clinical Program Update and Reports Second Quarter 2022 Financial Results
08/15/2022 12:30 PM
WARREN, N.J. , Aug. 15, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial More News |
|
|
|
 Our goal is to become a leader in developing and commercializing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. |
Bellerophon Therapeutics Inc. News ReleaseA Collection of Bellerophon Therapeutics Inc. News Release Bellerophon Therapeutics Announces Completion of Enrollment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease
01/18/2023 09:05 PM
Enrollment concludes earlier than anticipated; pivotal top-line data now expected mid-2023 WARREN, N.J. , Jan. 18, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for Bellerophon Therapeutics Announces License Agreement for the Commercialization of INOpulse® in Greater China with Baylor BioSciences
01/05/2023 01:30 PM
Bellerophon to receive a license payment of $6 million, as well as royalties on net sales in Greater China WARREN, N.J. , Jan. 05, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing Bellerophon Provides Clinical Program Update and Reports Third Quarter 2022 Financial Results
11/14/2022 01:30 PM
Ongoing INOpulse® REBUILD Phase 3 trial enrollment completion expected in the first quarter of 2023, with pivotal top-line data readout anticipated in the third quarter of 2023 WARREN, N.J. , Nov. 14, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the Bellerophon Announces FDA Acceptance of Change to Ongoing Phase 3 REBUILD Study of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease
09/27/2022 12:30 PM
New study size of 140 patients for the REBUILD Study, without modifying trial objective or endpoints and maintaining power of >90% for the primary endpoint Independent Data Monitoring Committee agreed that the new targeted study size is appropriate Enrollment now expected to conclude in Q1 2023, Bellerophon Provides Clinical Program Update and Reports Second Quarter 2022 Financial Results
08/15/2022 12:30 PM
WARREN, N.J. , Aug. 15, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial More News |